Tenaya Therapeutics grants CFO stock options
Tenaya Therapeutics, Inc. granted Chief Financial Officer Eric J. Hyllengren a stock option covering 1,650,000 shares of common stock with an exercise price of 0.8365 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Tenaya Therapeutics, Inc. granted Chief Financial Officer Eric J. Hyllengren a stock option covering 1,650,000 shares of common stock with an exercise price of 0.8365 per share. The option was issued under the 2024 Inducement Equity Incentive Plan, vests 25% after one year then monthly until fully vested, and expires on July 12, 2036.
Insider Trade Summary
Grant/Award: 1,650,000 shares
Grant/Award
1 txn
Insider
Hyllengren Eric J
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) F1 | 1,650,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to buy) — 1,650,000 contracts (Direct)
Footnotes (1)
- F1. Option granted pursuant to the Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan. Option will vest as to 1/4th of the total number of shares subject to the option on the one-year anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.
Key Figures
Option Grant Size: 1,650,000 shares
Exercise Price: 0.8365 per share
Shares After Transaction: 1,650,000 shares
+2 more
5 metrics
Option Grant Size
1,650,000 shares
Stock option covering common stock granted to CFO Eric J. Hyllengren
Exercise Price
0.8365 per share
Exercise price of the stock option granted to the CFO
Shares After Transaction
1,650,000 shares
Total derivative shares following the reported stock option grant
Exercise Date
2027-07-13
Date from which the stock option is stated as exercisable
Expiration Date
2036-07-12
Date on which the stock option expires if not exercised
Key Terms
Stock Option (Right to buy), Inducement Equity Incentive Plan, vest, underlying security
4 terms
Stock Option (Right to buy) financial
"security_title: Stock Option (Right to buy)"
Inducement Equity Incentive Plan financial
"Option granted pursuant to the Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan."
An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.
vest financial
"Option will vest as to 1/4th of the total number of shares subject to the option"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
underlying security financial
"underlying_security_title: Common Stock; underlying_security_shares: 1650000.0000"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock option grant did Tenaya Therapeutics (TNYA) give its CFO?
Tenaya Therapeutics granted CFO Eric J. Hyllengren a stock option for 1,650,000 shares of common stock with an exercise price of 0.8365 per share, issued as an inducement award under the company’s 2024 Inducement Equity Incentive Plan.
What is the exercise price of the new Tenaya Therapeutics (TNYA) CFO stock option?
The option granted to the CFO has an exercise price of 0.8365 per share. This means Hyllengren can purchase Tenaya Therapeutics common stock at 0.8365 per share once the option is vested and exercisable, subject to the plan’s terms.
How does the CFO’s new Tenaya Therapeutics (TNYA) option vest?
The option vests 25% of the 1,650,000 shares on the one-year anniversary of the grant date, then 1/48th of the total shares on each monthly anniversary thereafter until fully vested, as described in the inducement plan footnote.
When does the new Tenaya Therapeutics (TNYA) CFO option become exercisable and when does it expire?
The grant specifies an exercise date of July 13, 2027 and an expiration date of July 12, 2036. These dates define when the option can be exercised and the final date by which any vested portion must be exercised.
Under what plan was the Tenaya Therapeutics (TNYA) CFO option granted?
The option was granted under the Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan. The footnote notes it as an inducement grant, with vesting tied to time-based service conditions over a multi-year period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates